ReviewCurrent atherosclerosis reports2023
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know.
Review in Current atherosclerosis reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 28 citations in OpenAlex.
- Percentage of Low-Attenuation Epicardial Adipose Volume (LAAV%) as an Independent Predictor of Coronary Microvascular Dysfunction: A Retrospective Cohort Study.Reviews in cardiovascular medicine · 2026Article
- Coronary Microvascular Dysfunction: Epidemiology, Pathophysiology, Diagnosis, and Treatment.MedComm · 2026Review
- DNA/RNA Methylation-Driven Coronary Microvascular Dysfunction: Emerging Pathogenic Mechanisms and Therapeutic Opportunities for Heart Failure in Diabetes.Cardiovascular drugs and therapy · 2026Review
- Coronary microvascular function in patients with sepsis and myocardial injury: an invasive coronary physiology study.Critical care (London, England) · 2026Observational
- Coronary Microvascular Dysfunction and Lipid Molecules: Pathophysiological Mechanisms, Clinical Assessment, and Therapeutic Implications.Journal of personalized medicine · 2026Review
- The value of retinal microvascular features in predicting risk stratification and long-term prognosis of patients with acute coronary syndrome.BMC ophthalmology · 2026Article
- Type 2 Myocardial Infarction: Navigating Diagnostic Pathways and Therapeutic Crossroads Between Invasive and Conservative Strategies.Journal of clinical medicine · 2026Review
- Coronary microvascular dysfunction in HFpEF: pathophysiologic mechanisms, diagnosis, treatments, and the amplifying potential of sepsis.Frontiers in medicine · 2026Review
- Coronary angiography-derived microcirculatory resistance predicts adverse cardiovascular events in elderly with unstable angina post-percutaneous coronary intervention.Frontiers in aging · 2026Article
- Correlation between calcium levels and coronary microvascular disease in high-altitude environments: nested case-control study.Frontiers in cardiovascular medicine · 2026Article
- Coronary Microvascular Dysfunction Related to Hydroxychloroquine-Induced Cardiomyopathy.JACC. Case reports · 2025Article
- Retinal optical coherence tomography angiography (OCTA) biomarkers of cardiovascular disease: a review article.Eye (London, England) · 2025Review
- ARNT-dependent HIF-2α signaling protects cardiac microvascular barrier integrity and heart function post-myocardial infarction.Communications biology · 2025Article
- Advances in the diagnosis and management of post-percutaneous coronary intervention coronary microvascular dysfunction: Insights into pathophysiology and metabolic risk interactions.World journal of cardiology · 2025Review
- Sensitivity of coronary hemodynamics to vascular structure variations in health and disease.Scientific reports · 2025Article
- Coronary microvascular dysfunction: a review of its association with extracardiac organ pathologies.Frontiers in cardiovascular medicine · 2025Review
- Coronary microcirculation dysfunction causing ischemia with non-obstructive coronary arteries: a case report.Frontiers in cardiovascular medicine · 2025Article
- Prognostic Value of the Triglyceride-Glucose Index Combined with Non-HDL-C/HDL-C Ratio for Predicting Coronary Microvascular Dysfunction in ACS Patients Post-PCI.International journal of general medicine · 2025Article
- Coronary Microvascular Dysfunction Is Associated With Augmented Lysosomal Signaling in Hypercholesterolemic Mice.Journal of the American Heart Association · 2024Article
- Coronary Microvascular Dysfunction is Associated with Augmented Lysosomal Signaling in Hypercholesterolemic Mice.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewAbnormal structure and function of the coronary microvasculature have been implicated in the pathophysiology of multiple cardiovascular disease processes. This article reviews recent research progress related to coronary microvascular dysfunction (CMD) and salient clinical takeaways. RECENT
findingsCMD is prevalent in patients with signs and symptoms of ischemia and no obstructive epicardial coronary artery disease (INOCA), particularly in women. CMD is associated with adverse outcomes, including most frequently the development of heart failure with preserved ejection fraction. It is also associated with adverse outcomes in patient populations including hypertrophic cardiomyopathy, dilated cardiomyopathy, and acute coronary syndromes. In patients with INOCA, stratified medical therapy guided by invasive coronary function testing to define the subtype of CMD leads to improved symptoms. There are invasive and non-invasive methodologies to diagnose CMD that provide prognostic information and mechanistic information to direct treatment. Available treatments improve symptoms and myocardial blood flow; ongoing investigations aim to develop therapy to improve adverse outcomes related to CMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.